W Nathaniel Brennen1, L Nelleke Kisteman1, John T Isaacs1. 1. Department of Oncology, Prostate Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Abstract
BACKGROUND: Carcinoma-associated fibroblasts (CAFs) are a dominant component of the tumor microenvironment with pro-tumorigenic properties. Despite this knowledge, their physiologic origins remain poorly understood. Mesenchymal stem cells (MSCs) can be recruited from the bone marrow to areas of tissue damage and inflammation, including prostate cancer. MSCs can generate and have many overlapping properties with CAFs in preclinical models. METHODS: Multiparameter flow cytometry and multipotent differentiation assays used to define MSCs in primary prostate stromal cultures derived from young (<25 yrs) organ donors and prostate cancer patients compared with bone marrow-derived stromal cultures. Population doubling times, population doublings, cell size, and differentiation potential determined under multiple culture conditions, including normoxia, hypoxia, and a variety of media. TGF-β measured by ELISA. RESULTS: MSCs and stromal progenitors are not only present in normal and malignant prostate tissue, but are quickly selected for in primary stromal cultures derived from these tissues; becoming the dominant population within just a few passages. Growth potential inversely associated with TGF-β concentrations. All conditions generated populations with an average cell diameter >15 µm. All cultures tested had the ability to undergo osteogenic and chondrogenic differentiation, but unlike bone marrow-derived MSCs, primary stromal cultures derived from normal prostate tissue lack adipogenic differentiation potential. In contrast, a subset of stromal cultures derived from prostate cancer patients retain the ability to differentiate into adipocytes; a property that is significantly suppressed under hypoxic conditions in both bone marrow- and prostate-derived MSCs. CONCLUSIONS: Primary prostate stromal cultures are highly enriched in cells with an MSC or stromal progenitor phenotype. The use of primary cultures such as these to study CAFs raises interesting implications when considering their overlapping properties. The lack of adipogenesis in stromal cultures derived from normal prostates suggests they have a lineage-restricted progenitor phenotype. The retention of adipogenic differentiation in cultures from a subset of prostate cancer patients suggests the active recruitment of less committed progenitors or MSCs from the bone marrow as a function of disease progression. This recruitment can potentially be exploited for prognostic purposes or a cell-based platform for the systemic delivery of cytotoxic agents to sites of prostate cancer.
BACKGROUND:Carcinoma-associated fibroblasts (CAFs) are a dominant component of the tumor microenvironment with pro-tumorigenic properties. Despite this knowledge, their physiologic origins remain poorly understood. Mesenchymal stem cells (MSCs) can be recruited from the bone marrow to areas of tissue damage and inflammation, including prostate cancer. MSCs can generate and have many overlapping properties with CAFs in preclinical models. METHODS: Multiparameter flow cytometry and multipotent differentiation assays used to define MSCs in primary prostate stromal cultures derived from young (<25 yrs) organ donors and prostate cancerpatients compared with bone marrow-derived stromal cultures. Population doubling times, population doublings, cell size, and differentiation potential determined under multiple culture conditions, including normoxia, hypoxia, and a variety of media. TGF-β measured by ELISA. RESULTS: MSCs and stromal progenitors are not only present in normal and malignant prostate tissue, but are quickly selected for in primary stromal cultures derived from these tissues; becoming the dominant population within just a few passages. Growth potential inversely associated with TGF-β concentrations. All conditions generated populations with an average cell diameter >15 µm. All cultures tested had the ability to undergo osteogenic and chondrogenic differentiation, but unlike bone marrow-derived MSCs, primary stromal cultures derived from normal prostate tissue lack adipogenic differentiation potential. In contrast, a subset of stromal cultures derived from prostate cancerpatients retain the ability to differentiate into adipocytes; a property that is significantly suppressed under hypoxic conditions in both bone marrow- and prostate-derived MSCs. CONCLUSIONS: Primary prostate stromal cultures are highly enriched in cells with an MSC or stromal progenitor phenotype. The use of primary cultures such as these to study CAFs raises interesting implications when considering their overlapping properties. The lack of adipogenesis in stromal cultures derived from normal prostates suggests they have a lineage-restricted progenitor phenotype. The retention of adipogenic differentiation in cultures from a subset of prostate cancerpatients suggests the active recruitment of less committed progenitors or MSCs from the bone marrow as a function of disease progression. This recruitment can potentially be exploited for prognostic purposes or a cell-based platform for the systemic delivery of cytotoxic agents to sites of prostate cancer.
Authors: Woosook Kim; David A Barron; Rebeca San Martin; Keith S Chan; Linda L Tran; Feng Yang; Steven J Ressler; David R Rowley Journal: Proc Natl Acad Sci U S A Date: 2014-10-13 Impact factor: 11.205
Authors: K G Birukov; M G Frid; J D Rogers; V P Shirinsky; V E Koteliansky; J H Campbell; G R Campbell Journal: Exp Cell Res Date: 1993-01 Impact factor: 3.905
Authors: Robert M Hughes; Brian W Simons; Hamda Khan; Rebecca Miller; Valentina Kugler; Samantha Torquato; Debebe Theodros; Michael C Haffner; Tamara Lotan; Jessie Huang; Elai Davicioni; Steven S An; Ryan C Riddle; Daniel L J Thorek; Isla P Garraway; Elana J Fertig; John T Isaacs; W Nathaniel Brennen; Ben H Park; Paula J Hurley Journal: Cancer Res Date: 2019-05-23 Impact factor: 12.701
Authors: Oren Levy; W Nathaniel Brennen; Edward Han; David Marc Rosen; Juliet Musabeyezu; Helia Safaee; Sudhir Ranganath; Jessica Ngai; Martina Heinelt; Yuka Milton; Hao Wang; Sachin H Bhagchandani; Nitin Joshi; Neil Bhowmick; Samuel R Denmeade; John T Isaacs; Jeffrey M Karp Journal: Biomaterials Date: 2016-03-17 Impact factor: 12.479
Authors: Timothy E Krueger; Daniel L J Thorek; Alan K Meeker; John T Isaacs; W Nathaniel Brennen Journal: Prostate Date: 2018-11-28 Impact factor: 4.104
Authors: Peio Errarte; Rosa Guarch; Rafael Pulido; Lorena Blanco; Caroline E Nunes-Xavier; Maider Beitia; Javier Gil; Javier C Angulo; José I López; Gorka Larrinaga Journal: PLoS One Date: 2016-12-29 Impact factor: 3.240
Authors: W Nathaniel Brennen; Baohui Zhang; Ibrahim Kulac; L Nelleke Kisteman; Lizamma Antony; Hao Wang; Alan K Meeker; Angelo M De Marzo; Isla P Garraway; Samuel R Denmeade; John T Isaacs Journal: Oncotarget Date: 2017-07-18
Authors: Binod Kumar; Avi Z Rosenberg; Su Mi Choi; Karen Fox-Talbot; Angelo M De Marzo; Larisa Nonn; W Nathaniel Brennen; Luigi Marchionni; Marc K Halushka; Shawn E Lupold Journal: Sci Rep Date: 2018-05-08 Impact factor: 4.379
Authors: W Nathaniel Brennen; Daniel L J Thorek; Wen Jiang; Timothy E Krueger; Lizamma Antony; Samuel R Denmeade; John T Isaacs Journal: Immunotherapy Date: 2020-11-05 Impact factor: 4.196
Authors: W Nathaniel Brennen; Huong Nguyen; Susan L Dalrymple; Stephanie Reppert-Gerber; Jeesun Kim; John T Isaacs; Hans Hammers Journal: Oncotarget Date: 2016-11-01